Sale of genetic testing company raises concerns about privacy of 23andMe’s 15 million customers.
Regeneron Pharmaceuticals has bought the genetic testing company 23andMe, a company once valued at $6bn, for $256m through a bankruptcy…
Regeneron buys 23andMe for $256m after bankruptcy | Business and Economy
